Aspen's personalized Parkinson's therapy shows early promise

Parkinson's gets a personalized cell punch — Aspen's experimental therapy wins a name and keeps showing promise

Aspen Neuroscience on Wednesday reported that its experimental personalized cell therapy for Parkinson's disease continues to show encouraging early results, alongside a milestone that signals the program is maturing toward regulatory review: the World Health Organization has formally adopted "Sasineprocel" as the international nonproprietary name for the company's investigational therapy ANPD001.

The naming, also cleared by the American Medical Association's USAN Council, is more than ceremonial — it means regulators and pharmacologists worldwide now have a standardized identifier for the therapy as it moves through clinical testing. For Aspen, it's validation that the program is tracking toward a future submission.

Sasineprocel is an autologous dopaminergic neuron precursor cell therapy — meaning each dose is made from the patient's own cells. The process starts with a small skin biopsy, which is reprogrammed into induced pluripotent stem cells (iPSCs), then differentiated into neurons designed to replace those lost to Parkinson's. The cells are delivered via image-guided intracranial injection into the putamen. Because the cells come from the patient, there is no need for immunosuppressive drugs — a meaningful advantage over donor-derived or allogeneic cell therapies, which require patients to suppress their immune systems to prevent rejection.

Aspen's manufacturing process includes quality checks at every stage using the company's proprietary machine-learning-based genomics tests. CEO Damien McDevitt called earning the global naming rights "an important milestone" and said the company is committed to bringing the therapy to patients "who are awaiting transformative therapies with the potential to slow or stop the progression of this devastating disease."

The therapy is being evaluated in the Phase 1/2a ASPIRO study in patients with moderate to advanced Parkinson's disease. The company has not disclosed the specific efficacy data from the ongoing trial, citing the confidential nature of the study, but called the early results "encouraging." Sasineprocel has received Fast Track designation from the FDA — a status that is meant to expedite review of therapies that address serious conditions with unmet need.

The personalized iPSC approach has been in development for more than two decades, with the first animal studies dating to the early 2000s. What has changed is the manufacturing and quality control infrastructure needed to make individualized cell products at scale — and Aspen is among the first companies to attempt this in a registrational-stage trial. Whether the approach can be produced consistently and affordably enough to reach large numbers of patients remains an open question the company has yet to fully answer.

Aspen says it is the most advanced autologous cell therapy in the United States for Parkinson's disease.